IMRX ▼ -0.3% - Immuneering Corporation
$IMRX - Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
04-NOV-2026 07:30 AM ET
Share this post
More filings for $IMRX
IMRX ▲ +0.5% - Immuneering CorporationOct 29, 2026IMRX ▼ -2.4% - Immuneering CorporationOct 26, 2026IMRX ▲ +4.2% - Immuneering CorporationOct 2, 2026IMRX ▲ +2.1% - Immuneering CorporationSep 28, 2026IMRX ▲ +1.5% - Immuneering CorporationSep 10, 2026IMRX ▼ -0.4% - Immuneering CorporationSep 3, 2026
View full $IMRX filing history →💬 Comments
Loading comments…
Leave a comment